Bibliography
- Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010;31:53-9
- Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251:ii4-9
- European Medicines Agency. Guideline on similar biological medicinal products. 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf [Last accessed 16 November 2012]
- Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30:1087-92
- Reichert JM. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. MAbs 2011;3:223-40
- Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
- Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413-15
- Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010;28:917-24
- Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available from: http://clinicaltrials.gov/ct2/home [Last accessed 2 November 2012]
- EU Clinical Trials Register. Available from: https://www.clinicaltrialsregister.eu/index.html [Last accessed 2 November 2012]
- Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012;526:159-66
- European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf [Last accessed 2 November 2012]
- Calvo B, Zuniga L. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development. Curr Med Chem 2012;19:4445-50
- Singh M, Lima A, Molina R, Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 2010;28:585-93
- European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf [Last accessed 2 November 2012]
- Biosimilar News. Biosimilar mabs age: coming so fast. 2011. Available from: http://www.biosimilarnews.com/biosimilar-mabs-age-coming-so-fast [Last accessed 15 November 2012]
- Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4:419-25